This article is more than 5 years old. Information may no longer be current.

Retaane granted Australian marketing approval

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUNENBERG, Switzerland — Anecortave acetate as a treatment for subfoveal choroidal neovascularization in exudative age-related macular degeneration was granted regulatory approval by Australian authorities, according to the drug’s maker.

Retaane (anecortave acetate for juxtascleral depot 15 mg, Alcon) was granted approval in Australia “for all lesions with a classic component,” said Scott Krueger, PhD, Alcon’s vice president of pharmaceutical research and development, in a press release from the company.

The drug is an angiostatic cortisene that inhibits the abnormal growth of blood vessels, according to the release. Retaane is administered every 6 months, using a blunt-tipped, curved cannula to deliver the drug behind the eye, the release said.

Alcon also said it will provide Retaane to the National Eye Institute for a study in patients with wet AMD. The trial will “investigate the long-term safety and potential efficacy of Retaane suspension in patients with all forms of wet AMD who are undergoing intravitreal Avastin (bevacizumab, Genentech) therapy.”